Eli Lilly (LLY) is making a big bet that the best way to treat disease is to stop it before it starts. On Tuesday, the drugmaker announced it will acquire three biotech companies—Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc.—in a move that significantly expands its infectious disease research portfolio. The total price tag could exceed $3.8 billion if all milestone payments are met.

The acquisitions are part of a broader strategy to invest in vaccines and prevention technologies that reduce long-term health risks tied to infections. Think shingles, drug-resistant bacteria, and even Epstein-Barr virus—all of which have been linked to more serious conditions like neurological disorders, cancer, and infertility down the road.

“For 150 years, Lilly has advanced medicines to address the world’s most pressing health challenges,” the company said, noting that infectious diseases remain a major source of global illness and long-term complications.

A Prevention-First Philosophy

Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, framed the deals as a deliberate shift toward stopping disease at its source. “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Skovronsky said. “Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility.”

That’s a compelling argument. Instead of waiting for someone to get sick and then throwing a blockbuster drug at the problem, Lilly is investing in vaccines that could keep people healthy in the first place. It’s a longer-term play, but one that could pay off handsomely if the science holds up.

Breaking Down the Deals

Here’s what Lilly is buying:

Curevo Inc. is developing a shingles vaccine called amezosvatein, currently in Phase 2 trials. The vaccine has shown immune responses comparable to the current standard of care, but with a much better side effect profile—fatigue, chills, and injection-site pain were reduced by more than half. Curevo shareholders could receive up to $1.5 billion in cash, including upfront and milestone payments.

LimmaTech Biologics AG focuses on vaccines against drug-resistant bacterial pathogens, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. The acquisition could total up to $780 million. This is a direct play on the growing threat of antimicrobial resistance—sometimes called the “silent pandemic.”

Vaccine Company, Inc. (yes, that’s its actual name) is working on nanoparticle-based vaccine technologies, including a candidate for Epstein-Barr Virus. The deal could reach $1.55 billion in milestone-based payments. EBV is a common virus that’s been linked to multiple sclerosis and certain cancers, so a vaccine could have huge public health impact.

All three transactions are subject to customary closing conditions and regulatory approvals.

What This Means for Lilly’s Stock

Investors seem to like the news. Lilly shares were up 1.28% at $1,078.66 on Tuesday. The stock has had a strong run over the past year, gaining 46.85%. It’s trading well above key moving averages—10.6% above the 20-day simple moving average and 16.1% above the 200-day SMA—which typically signals a bullish trend.

Technically, the stock faces near-term resistance at $1,095.50, with support at $943.50. The MACD indicator is above its signal line, suggesting that bullish momentum is building. Unless something changes dramatically, the trend looks favorable.

Earnings and Analyst Outlook

Lilly is scheduled to report its next quarterly results on August 6, 2026. Analysts expect earnings per share of 880 cents, up from 631 cents a year ago, on revenue of $20.43 billion, up from $15.56 billion. The stock trades at a premium valuation of 37.8 times earnings.

The analyst consensus is a Buy, with an average price target of $1,241. Recent moves include Barclays raising its forecast to $1,400 (Overweight), Guggenheim maintaining $1,183 (Buy), and Wolfe Research keeping $1,325 (Outperform).

So, Wall Street is on board. The question is whether Lilly’s prevention bet will pay off in the long run. If these vaccines succeed, the company could be sitting on a pipeline that not only saves lives but also generates billions in revenue. And that’s a pretty good prescription for shareholders.